Price relief for hypertensive Filipinos

Nearly eight million Filipinos have hypertension. Stressfully high medicine prices worsen their ailment. But relief is probably in sight. The state-owned Philippine International Trading Corp. is seeking to void the local patent of the hot-selling hypertension drug Norvasc. And it has strong legal basis for it. Norvasc sells for P41.41 per 5-mg tablet in the Philippines. Senator MAR Roxas says the same Norvasc formulation retails in India for only P5.77. The PITC should be allowed to legally import from India, he adds, "to benefit 7.76 million hypertensive Filipinos." (ABS-CBN Interactive)

EVEN if Congress is on recess due to the elections, there is a sustained effort to hasten the approval of Senate Bill (SB) 2263 which seeks to lower the prices of medicines, said Senator Manuel "Mar" Roxas III. "Even if Congress is in recess for the national polls, we, together with fellow legislators across party lines, our staff and various stakeholders are engaged in constant consultations in order to build a consensus on the lower priced medicines bill," he said.
(Sun.Star Manila)

“Roxas Amendments” consistent with US Appellate Court Decision on Norvasc

Senator Mar Roxas expressed victory over the recent decision of the United States’ highest appellate court invalidating the patent of Pfizer over amlodipine besylate, a hypertension drug under the brand name Norvasc.

He said the decision last week of the US Court of Appeals for the Federal Circuit is consistent with his proposed amendments to the Intellectual Property Code, or Senate Bill No. 2263, also known as the cheaper medicines bill. (Senate)

Affordable medicines

FOR a change, the Senate took the initiative on an important bill ahead of the House of Representatives, which now plays follow-the-leader on the issue of costly medicines. The Senate, voting 20-0, approved on third and final reading Senate Bill 2263, authored by Sen. Mar Roxas, which seeks to amend the Intellectual Property Code to make medicines more accessible to the poor and the middle-class. (Manila Times)